Back to search

Peptide record

TPDB11238

Human neutrophil peptide-1 (HNP-1) HNP-1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
30 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11238
Human neutrophil peptide-1 (HNP-1) HNP-1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP pep-lab Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP DRAVP 2.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 30-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Physicochemical Analysis
C150H228N44O38S6
NDHKMSV
C
3448.09
8.30
4
1
13
+3
-2.95
0.300
65.33
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
10345
300.02
11
Residue Composition
number
4
A
4
R
0
N
0
D
6
C
1
E
1
Q
3
G
0
H
3
I
1
L
0
K
0
M
1
F
1
P
0
S
1
T
1
W
3
Y
0
V
Amino Acid Distribution
A: 4 R: 4 N: 0 D: 0 C: 6 E: 1 Q: 1 G: 3 H: 0 I: 3 L: 1 K: 0 M: 0 F: 1 P: 1 S: 0 T: 1 W: 1 Y: 3 V: 0
Chemical Descriptors
30
C150H228N44O38S6
3448.09
8.30
+3
-2.95
0.300
Free
L
Not Available Cyclic(C2-C30, C4-C19,C9-C29)
Free
Anticancer Antimicrobial
Homo sapiens
Evidence Records 25 records
Evidence 1 Activity

Activity

MIC
Antibacterial
39.7 µg/mL

Target

L. monocytogenes

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-n
Evidence 2 Activity

Activity

MIC
Antibacterial
2.2 µg/mL

Target

S.epidermis

Source & Reference

dbAMP DRAMP

Other

Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimuri
Evidence 3 Activity

Activity

MIC
Antibacterial
5.2-21.2 µg/mL

Target

Staphylococcus aureus or MRSA

Source & Reference

dbAMP DRAMP

Other

difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/
Evidence 4 Activity

Activity

MIC
Antibacterial
1.8-11.9 µg/mL

Target

Stenotrophomonas maltophilia

Source & Reference

dbAMP DRAMP

Other

eus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/ml). Also B. burgdorferi ( Lusitani et al., 2002 ). Viruses: Human HNP-1 blocks papillomaviru
Evidence 5 Activity

Activity

Not Available
Anticancer

Target

Fibrosarcoma
Not Available
Fibrous connective tissue

Assay & Model

Not Available
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1985

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 6 Activity

Activity

IC50
IC50 = 2.2 ± 0.3 µM
Anticancer
2.2

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Cytotoxicity assay (LIVE/DEAD® Viability/Cytotoxicity Assay Kit (L-3224))
4h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2015
Evidence 7 Activity

Activity

MIC
Antifungal
39.7 µg/mL

Target

L. monocytogenes

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-n
Evidence 8 Activity

Activity

MIC
Antifungal
2.2 µg/mL

Target

S.epidermis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimuri
Evidence 9 Activity

Activity

MIC
Antifungal
5.2-21.2 µg/mL

Target

Staphylococcus aureus or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/
Evidence 10 Activity

Activity

MIC
Antifungal
1.8-11.9 µg/mL

Target

Stenotrophomonas maltophilia

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

eus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/ml). Also B. burgdorferi ( Lusitani et al., 2002 ). Viruses: Human HNP-1 blocks papillomaviru
Evidence 11 Activity

Activity

MIC
Antiparasitic
39.7 µg/mL

Target

L. monocytogenes

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-n
Evidence 12 Activity

Activity

MIC
Antiparasitic
2.2 µg/mL

Target

S.epidermis

Source & Reference

dbAMP 3.0 DRAMP

Other

Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimuri
Evidence 13 Activity

Activity

MIC
Antiparasitic
5.2-21.2 µg/mL

Target

Staphylococcus aureus or MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/
Evidence 14 Activity

Activity

MIC
Antiparasitic
1.8-11.9 µg/mL

Target

Stenotrophomonas maltophilia

Source & Reference

dbAMP 3.0 DRAMP

Other

eus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/ml). Also B. burgdorferi ( Lusitani et al., 2002 ). Viruses: Human HNP-1 blocks papillomaviru
Evidence 15 Activity

Activity

MIC
Antiviral
39.7 µg/mL

Target

L. monocytogenes

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-n
Evidence 16 Activity

Activity

MIC
Antiviral
2.2 µg/mL

Target

S.epidermis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Killed C. difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimuri
Evidence 17 Activity

Activity

MIC
Antiviral
5.2-21.2 µg/mL

Target

Staphylococcus aureus or MRSA

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

difficile. Active against L. monocytogenes (MIC 39.7 ug/ml), S.epidermis (MIC 2.2 ug/ml), S. aureus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/
Evidence 18 Activity

Activity

MIC
Antiviral
1.8-11.9 µg/mL

Target

Stenotrophomonas maltophilia

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

eus or MRSA (MIC 5.2-21.2 ug/ml), B. subtilis, Gram-negative E. coli, S. typhimurium, and S. maltophilia (MIC 1.8-11.9 ug/ml). Also B. burgdorferi ( Lusitani et al., 2002 ). Viruses: Human HNP-1 blocks papillomaviru
Evidence 19 Activity

Activity

15% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
15% Hemolysis | 20 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines | Antimicrob Agents Chemother | 2005
Evidence 20 Activity

Activity

20% Hemolysis
Toxicity
40 µM
Hemolytic Cytotoxic
20% Hemolysis | 40 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines | Antimicrob Agents Chemother | 2005
Evidence 21 Activity

Activity

2.8% Cytotoxicity
Toxicity
5 µg/mL
Cytotoxic
2.8% Cytotoxicity | 5 | µg/mL | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. | Eur Respir J | 2000
Evidence 22 Activity

Activity

10.5% Cytotoxicity
Toxicity
40 µg/mL
Cytotoxic
10.5% Cytotoxicity | 40 | µg/mL | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. | Eur Respir J | 2000
Evidence 23 Activity

Activity

1% Hemolysis
Toxicity
50-100 µM
Hemolytic Cytotoxic
1% Hemolysis | 50-100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis. | Int J Antimicrob Agents | 2010
Evidence 24 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.34206990]No cytotoxicity on HEK293T cells up to 50 µg/mL.

Source & Reference

NA
DRAMP
Viruses. 2021 Jun 26 13(7):1246.##Proteomics. 2009 Mar 9(5):1364-1373.##Antimicrob Agents Chemother. 2005 Jan 49(1):269-275.##Proc Natl Acad Sci U S A. 2004 May 11 101(19):7363-8.
Evidence 25 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.